文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺立体定向体部放疗后泌尿生殖与肠道生活质量的患者及剂量学预测因素:一项多中心试验的二次分析

Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-07-26

该研究基于一项2期多中心试验的二次分析,纳入18家机构259例低危或中危前列腺癌患者,接受机器人立体定向体部放疗38 Gy分4次连续日照射,未使用雄激素剥夺治疗。结果发现直肠最大剂量与1个月和2年肠道生活质量相关,2年时直肠最大剂量大于中位数37.4 Gy者中度或重度总体肠道问题的比例显著高于小于中位数者(11% vs 2%,Fisher精确检验P=.008);膀胱和尿道剂量与1个月或2年泌尿生活质量无关。

要点

  • 直肠最大剂量与1个月和2年肠道生活质量相关,2年时大于中位数37.4 Gy者中度或重度总体肠道问题比例显著更高(11% vs 2%,P=.008)。
  • 膀胱和尿道剂量与1个月或2年泌尿生活质量均无关。
  • 既往经尿道前列腺电切术和临床靶区大小与2年尿失禁相关。

核心结论

  • 直肠最大剂量与1个月和2年肠道生活质量相关,膀胱和尿道剂量与泌尿生活质量无关。
  • 既往经尿道前列腺电切术和临床靶区大小与2年尿失禁相关。

研究设计与样本

  • 多中心2期试验的二次分析,2007年至2012年纳入18家机构259例低危或中危前列腺癌患者。
  • 患者接受机器人立体定向体部放疗38 Gy分4次连续日照射,未使用雄激素剥夺治疗。
  • 使用Foley导尿管模拟定位勾画尿道,临床靶区为前列腺(低危)或前列腺加1 cm近端精囊(中危)。
  • 采用扩展前列腺癌指数综合量表在方案规定时间点评估治疗前及治疗后生活质量,使用线性回归分析1个月和2年生活质量相关因素。

主要发现

  • 生活质量数据在基线、1个月和2年时分别有98%、96%和84%可获取,中位年龄69岁。
  • 既往经尿道前列腺电切术和临床靶区大小与2年尿失禁相关。
  • 多变量分析中,老年患者2年梗阻/刺激症状有更差的趋势。
  • 膀胱和尿道剂量与1个月或2年泌尿生活质量均无关。
  • 2年时直肠最大剂量大于中位数37.4 Gy者中度或重度总体肠道问题比例显著高于小于中位数者(11% vs 2%,Fisher精确检验P=.008)。

关键数值与推荐

  • 2年时直肠最大剂量大于中位数37.4 Gy者中度或重度总体肠道问题比例为11%,小于中位数者为2%(Fisher精确检验P=.008)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is an emerging option for localized prostate cancer. However, there are no standard dosimetric guidelines, and normal tissue tolerances for extreme hypofractionation are not well defined. We analyzed dosimetric correlations with patient-reported urinary and bowel quality of life (QOL) on a prospective trial. METHODS AND MATERIALS: Patients with low- or intermediate-risk prostate cancer from 18 institutions were enrolled on a phase 2 trial from 2007 to 2012 and treated using robotic SBRT to 38 Gy in 4 fractions on consecutive days. No androgen deprivation was used. Patients received simulation with Foley catheter for urethral delineation. The clinical target volume was prostate (low-risk patients) or prostate plus 1 cm of proximal seminal vesicles (intermediate-risk patients). Multiple dosimetric measures for urethra, bladder, and rectum were prospectively recorded. QOL using the Expanded Prostate Cancer Index Composite was assessed before and after treatment at protocol-specific time points. Linear regression was used to assess factors associated with QOL at 1 month and 2 years. RESULTS: A total of 259 patients were enrolled. QOL data were available for 98%, 96%, and 84% at baseline, 1 month, and 2 years, respectively. Median age was 69 years. Prior transurethral resection of the prostate and clinical target volume size were associated with 2-year urinary incontinence. There was a trend toward worse 2-year obstruction/irritation in older patients on multivariable analysis. Bladder and urethral doses were not associated with either 1-month or 2-year urinary QOL. In contrast, rectum maximum dose was associated with both 1-month and 2-year bowel QOL. At 2 years, the proportion with moderate or big overall bowel problems (as defined by Expanded Prostate Cancer Index Composite-26) was significantly higher in patients with rectum maximum dose greater than versus less than the median 37.4 Gy (11% vs 2%, Fisher's exact test P = .008). CONCLUSIONS: These results provide novel data that contribute to a better understanding of patient and dosimetric factors associated with adverse QOL effects from prostate SBRT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang K, Chen RC, Kane BL, et al. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 30056080. doi:10.1016/j.ijrobp.2018.07.191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。